98%
921
2 minutes
20
Purpose: Early diagnosis of liver cancer requires highly sensitive detection of biomarkers. This study aims to develop a novel method for detecting circulating tumor DNA (ctDNA) in the serum of liver cancer patients, leveraging a catalytic hairpin self-assembly (CHA) signal amplification strategy combined with surface-enhanced Raman scattering (SERS) technology and nano-enzyme catalysis.
Methods: We synthesized Au@Pt@HP1-HP2@FeO nano-enzyme complexes, utilizing the SERS-enhancing properties of Pt-coated Au nanoparticles (Au@Pt) and the separation-enrichment capability of FeO magnetic beads. The complexes catalyzed the oxidation of colorless TMB by HO to produce blue ox-TMB, enabling quantitative detection of PIK3CA E542K mutant ctDNA. The assay's performance was validated using gold standard qRT-PCR.
Results: Under optimized conditions, the method achieved a detection limit for PIK3CA E542K as low as 4.12 aM. The assay demonstrated high sensitivity, specificity, and efficient magnetic separation, making it a robust tool for ctDNA detection.
Conclusion: This study presents a highly sensitive and specific detection platform for liver cancer early diagnosis, characterized by magnetic separation and nano-enzyme catalysis. The method holds significant clinical potential for the accurate and early detection of liver cancer biomarkers.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255329 | PMC |
http://dx.doi.org/10.2147/IJN.S531541 | DOI Listing |
Ann Med
December 2025
Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Background: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine carcinoma (NEC) with poor prognosis due to chemotherapy resistance. Molecular subtypes, including ASCL1, NEUROD1, YAP1 and POU2F3, have distinct clinical implications. POU2F3, linked to a tuft cell-like lineage, represents a non-neuroendocrine subtype found in SCLC and extrapulmonary NECs.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
An estimated 254 million people live with hepatitis B worldwide, with only 13% of people diagnosed and 3% receiving antiviral treatment. Without timely treatment, people with hepatitis B risk developing liver damage and liver cancer. In countries like Australia, where most people with hepatitis B are born in countries with higher prevalence, it is important that the knowledge and perceptions of hepatitis B in immigrant populations are explored to improve engagement in care.
View Article and Find Full Text PDFMed J Aust
September 2025
QIMR Berghofer, Brisbane, QLD.
Objective: To determine the cumulative incidence of overall and cause-specific mortality among Queensland residents admitted to hospital with cirrhosis during 2007-22, by cirrhosis aetiology.
Study Design: Retrospective cohort study; analysis of linked Queensland Hospital Admitted Patient Data Collection and Queensland Registry of Births, Deaths and Marriages data.
Setting, Participants: Adult Queensland residents (18 years or older) admitted to Queensland hospitals with cirrhosis during 1 July 2007 - 31 December 2022.
Magn Reson Med
September 2025
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Purpose: To develop and validate a fast, motion-robust, free-breathing abdominal 3D T1ρ mapping method by combining variable-density diamond radial k-space sampling with fast-MAPSS (magnetization-prepared angle-modulated partitioned-k-space spoiled gradient-echo snapshots).
Methods: 3D MAPSS T1ρ imaging was performed at 3T using five spin-lock time (TSL) pairs in phantom scans and three TSL pairs in nine healthy volunteers. Phantom experiments compared Cartesian sampling (reference) with stack-of-stars and diamond radial sampling.
Obesity (Silver Spring)
September 2025
Division of Diabetes and Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Objective: Vertical sleeve gastrectomy (VSG) promotes significant metabolic improvements, though the underlying molecular mechanisms are not fully understood. Emerging evidence suggests that small extracellular vesicles (sEVs) contribute to metabolic improvements post VSG, such as improved fatty liver disease or adipose tissue function; however, it is unclear how different organ-specific sEVs interact with various metabolic parameters. The objective of this study is to establish the role of organ-specific sEVs in the metabolic improvements post VSG.
View Article and Find Full Text PDF